🇺🇸 FDA
Patent

US 11591336

Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors

granted A61KA61K45/06A61P

Quick answer

US patent 11591336 (Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors) held by Relay Therapeutics, Inc. expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Relay Therapeutics, Inc.
Grant date
Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
54
CPC classes
A61K, A61K45/06, A61P, A61P19/06, A61P3/00